If Australia had paid English prices for the generic cholesterol-lowerer simvastatin during May 2010-October 2011, its Pharmaceutical Benefits Scheme (PBS) spending could have been reduced from A$150 million to just A$20 million, says a leading health economist.
Australia's "price disclosure" policy - agreed as part of the government/research-based industry Memorandum of Understanding (MoU) to reduce the prices of older PBS-listed drugs by requiring drugmakers to reveal to the government the actual price at which they sell their products to pharmacies - does reduce future prices, according to Professor Philip Clarke of the University of Melbourne, writing this week in the Medical Journal of Australia.
via pharmatimes.com
No comments:
Post a Comment